Table 2 The association between ESR1 (ERα) and ESR2 (ERβ) mRNA expression and clinico-pathological characteristics

Gender

Female

6

11.8 (5.7, 24.5)

0.2

14.6 (6.9, 58.1)

0.37

1.7 (1.1, 2.3)

0.31

4.1 (1.3, 5.9)

0.37

Male

28

6.9 (7.2, 17.8)

15.4 (5.6, 23.2)

1.8 (1.3, 3.0)

2.1 (1.8, 5.0)

Histology

AC

28

9.5 (6.5, 18.5)

0.4

14.3 (5.5, 23.6)

0.055

1.8 (1.3, 2.5)

0.39

2.1 (1.5, 5.9)

0.16

SCC

6

11.2 (6.9, 15.3)

22.6 (18.4, 25.2)

1.7 (1.1, 2.5)

3.1 (2.1, 6.0)

T-stage^a

pT1

8

8.4 (7.6,14.2)

0.24

9.5 (3.3, 15.8)

0.02

1.7 (1.2, 3.6)

0.53

2.0 (0.9, 5.4)

0.085

pT2

3

5.7 (2.5, 13.8)

5.7 (5.3, 8.9)

0.8 (0.7, 3.5)

1.7 (0.5, 1.8)

pT3

23

14.7 (6.3, 18.7)

20 (13, 31)

1.9 (1.35, 27)

3.1 (1.8, 5.6)

LN status^a

N0

15

7.8 (6.1, 13.4)

0.01

9.7 (5.4, 19.7)

0.02

1.4 (1.3, 2.7)

0.15

2.0 (1.0, 5.3)

0.11

N1

19

15.9 (7.8, 21.3)

18.2 (7.3, 40.5)

1.9 (1.4, 2.4)

3.1 (1.8, 7

Grade^a

Moderate

25

10.2 (6.7, 18.4)

15.3 (6.0, 22.5)

1.8 (1.2, 2.7)

2.8 (1.8, 6.1)

Poor

9

7.8 (5.4, 16.3)

19.7 (6.0, 36.6)

1.9 (1.3, 2.6)

1.8 (1.0, 5.1)

VI^a

No

21

8.8 (6.2, 22.3)

0.42

14.8 (5.1, 21.4)

0.07

1.9 (1.3, 2.9)

0.41

2.0 (0.9, 4.4)

0.01

Yes

13

10.2 (7.8, 16.9)

17.0 (10.7, 28.1)

1.8 (1.3, 2.3)

3.3 (2.9, 7.1)

BM

Yes

13

13.4 (6.4, 21.3

0.26

14.6 (6.1, 18.7)

0.31

2.1 (1.3, 5.9)

0.12

1.7 (1.2, 2.9)

0.054

No

15

6.3 (2.5, 16.6)

14.8 (5.1, 44.4)

1.9 (1.3, 2.3)

2.8 (1.7, 5.5)

CRM

No

23

13.4 (6.7, 21.3)

0.21

14.8 (5.7, 20.3)

0.12

1.9 (1.2, 2.7)

0.44

2.0 (1.0, 7.2)

0.09

Yes

11

8.6 (6.0, 16.6)

22.5 (7.3, 25.7)

1.8 (1.3, 2.4

2.1 (1.5, 3.1)